Journal Mobile Options
Table of Contents
Vol. 4, No. 5, 2007
Issue release date: July 2007
Neurodegenerative Dis 2007;4:386–391

Comprehensive Screening of a North American Parkinson’s Disease Cohort for LRRK2 Mutation

Johnson J. · Paisán-Ruíz C. · Lopez G. · Crews C. · Britton A. · Malkani R. · Evans E.W. · McInerney-Leo A. · Jain S. · Nussbaum R.L. · Foote K.D. · Mandel R.J. · Crawley A. · Reimsnider S. · Fernandez H.H. · Okun M.S. · Gwinn-Hardy K. · Singleton A.B.
aLaboratory of Neurogenetics, National Institute on Aging, bNeurogenetics Branch, National Institute of Neurological Disorders and Stroke and cGenetic Diseases Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Md.; dMedical Genetics, University of California, San Francisco, Calif., and eMovement Disorders Center, University of Florida, Gainesville, Fla., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Recently, mutations in LRRK2 encoding the protein dardarin have been linked to an autosomal dominant form of parkinsonism. Objective: To identify mutations causing Parkinson’s disease (PD) in a cohort of North Americans with familial PD. Methods: We sequenced exons 1–51 of LRRK2 in 79 unrelated North American PD patients reporting a family history of the disease. Results: One patient had a missense mutation (Thr2356Ile) while two others had the common Gly2019Ser mutation. In addition, 1 patient had a 4-bp deletion in close proximity to the exon 19 splice donor (IVS20+4delGTAA) that in vitro abrogates normal splicing. Conclusions: Our observations in the 79 North American patients indicate that mutations in LRRK2 are associated with approximately 5% of PD cases with a positive family history. The results also show that G2019S represents approximately half of the LRRK2 mutations in United States PD cases with a family history of the disease. We have identified two novel mutations in LRRK2.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Paisán-Ruíz C, Jain S, Evans EW, Gilks WP, Simón J, van der Brug M, et al: Cloning of the gene containing mutations that cause PARK8-linked Parkinson disease. Neuron 2004;44:595–600.
  2. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al: Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601–607.
  3. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.
  4. Hernandez DG, Paisán-Ruiz C, McInerney-Leo A, Jain S, Meyer-Lindenberg A, Evans EW, et al: Clinical and positron emission tomography of Parkinson’s disease caused by LRRK2. Ann Neurol 2005;57:453–456.
  5. Rogaeva E, Johnson J, Lang AE, Gulick C, Gwinn-Hardy K, Kawarai T, et al: Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol 2004;61:1898–1904.
  6. Hague S, Rogaeva E, Hernandez D, Gulick C, Singleton A, Hanson M, et al: Early-onset Parkinson’s disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol 2003;54:271–274.
  7. Johnson J, Hague SM, Hanson M, Gibson A, Wilson KE, Evans EW, et al: SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies. Neurology 2004;63:554–556.
  8. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al: Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605–608.
  9. D’Souza I, Schellenberg GD: tau Exon 10 expression involves a bipartite intron 10 regulatory sequence and weak 5′ and 3′ splice sites. J Biol Chem 2002;277:26587–26599.
  10. Nichols WC, Pankratz N, Hernandez D, Paisán-Ruíz C, Jain S, Halter CA, et al: Genetic screening for a single common LRRK2 mutation in familial Parkinson’s disease. Lancet 2005;365:410–412.
  11. Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, et al: A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet 2005;365:415–416.
  12. Di Fonzo A, Rohe CF, Ferreira J, Chien HF, Vacca L, Stocchi F, et al: A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson’s disease. Lancet 2005;365:412–415.
  13. Smith TF, Gaitatzes C, Saxena K, Neer EJ: The WD repeat: a common architecture for diverse functions. Trends Biochem Sci 1999;24:181–185.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50